- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
- The Hot Pink Party
You are here
Hayley McDaid, PhD
Assistant Professor, Medicine (Oncology)
Albert Einstein College of Medicine
Bronx, New York
Goal: To identify new therapeutic options for triple negative and BRCA-driven breast cancers.
Impact: Drs. McDaid and Horowitz are testing new drugs that may overcome common drug resistance and cause fewer side effects than currently approved therapies, while also investigating the reasons underlying relapse after chemotherapy. Their work could lead to improved outcomes for patients with aggressive breast cancer.
What’s next: The team will continue to screen novel targeted anti-cancer therapies in triple negative breast cancer (TNBC). They also plan to develop biomarkers to accurately detect senescent tumor cells. Senescent – or dormant – tumor cells are often resistant to anti-cancer treatment and are known to drive cancer recurrence that leads to metastasis.
While many breast cancer patients have excellent survival following anti-cancer therapy, some patients are resistant to treatment or may have an incomplete response, leading to relapse after a period of remission. The BCRF research led by Drs. McDaid and Horowitz is focused on defining the fate of cancer cells within a tumor population following therapy, especially those that are resistant to therapy. They are conducting laboratory studies to identify more effective and less toxic drugs for patients with TNBC and pursuing biomarkers of dormant tumor cells involved in metastasis and drug resistance.
Full Research Summary
Research area: Identifying targeted therapies and new combination approaches to counter drug resistance and improve outcomes for patients with triple negative and BCRA-driven breast cancer.
Impact: While many patients with triple negative breast cancer (TNBC) respond well to therapy, others have an incomplete response and/or relapse after a period of remission. Those who have inherited mutations in genes that control DNA damage, such as BRCA, often have a particularly high risk of relapse following treatment. Drs. McDaid and Horowitz are investigating the causes of resistance to therapy and testing existing and novel drugs that could overcome it.
Current research: The team is currently focused on the role of tumor cell dormancy and the immune microenvironment on drug resistance and tumor cell survival.
What they’ve learned so far. Their studies have shown that dormant cancer cells produce inflammatory proteins that can promote metastasis and drug resistance. They have been screening novel molecules that target the tubulin cytoskeleton – the cellular “scaffolding” – for evidence of anti-cancer activity in TNBC.
What’s next: The team will continue investigating potential drug candidates for TNBC that both strongly induce tumor cell death and have a low risk of inducing cellular dormancy.
Dr. Hayley McDaid received her PhD from the Queens University of Belfast, where she characterized the role of the cAMP-dependent protein kinase A signaling pathway in breast and ovarian cancer. These studies pioneered her present-day interest in targeted therapies, pharmacogenomics and rationally designed drug combinations.
Dr. McDaid's broad research theme in breast cancer is focused on investigating molecular mechanisms of action and resistance to novel therapeutics. She is interested in defining the ‘circuitry’ of breast cancer in the different molecular subtypes of triple negative tumors; and mechanisms by which tumors counteract the effects of therapy. As part of this focus, Dr. McDaid has been studying chemotherapy-mediated senescence, a type of growth arrest that is increasingly perceived as a deleterious outcome of treatment. Together with colleagues, she is interested in chemical-biological approaches to minimize the risk of developing senescence during treatment.